The latest financial statement is for the quarter ending 2025-09-30.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -712,184 | -1,292,788 |
| Stock-based compensation | 0 | 23,385 |
| Non-cash lease expense | 238 | 317 |
| Prepaid expenses | -4,597 | 4,230 |
| Accounts payable and other current liabilities | -53,896 | -595,644 |
| Net cash used in operating activities | -761,245 | -1,868,960 |
| Net change in cash and cash equivalents | -761,245 | -1,868,960 |
| Cash and cash equivalents at beginning of period | 5,606,863 | - |
| Cash and cash equivalents at end of period | 2,976,658 | - |
Inhibitor Therapeutics, Inc. (INTI)
Inhibitor Therapeutics, Inc. (INTI)